Clinical and preclinical studies have shown that the HER2/HER3/Akt pathway is highly implicated in trastuzumab resistance, where heterodimerization of HER family members and existence of p95HER2 is associated with breast cancer treatment [6, 50]. This evidence concerns the gene AKT1 and breast cancer.